Quotient Therapeutics
Generated by Meeveem AI
"Transforming somatic genomics insights into genetically validated breakthrough medicines"
About Quotient Therapeutics
Quotient Therapeutics is a biotechnology company headquartered in Cambridge, MA, with a UK genomics hub at Chesterford Research Park. It studies the genetic diversity created by somatic mutations within the body, identifying changes that cause or protect against disease. The company says its approach can uncover significant mutations in studies of 10 to 30 patients, providing genetically validated drug targets.
Founded by Flagship Pioneering in 2022, Quotient integrates DNA sequencing, artificial intelligence, computational biology and automation across research and development. It has collected somatic data across 15 diseases and validated its approach in autoimmune, cardiometabolic, rare and oncology diseases. Its current internal drug-development focus is autoimmune disease, alongside partnered programmes in other therapeutic areas.
Connected research disciplines
Quotient’s research workflows run from patient samples through target identification, biological validation and drug design. The company integrates AI and computational tools throughout this process, while its careers material describes academics and innovators collaborating across functions.
Pharmaceutical collaborations
The company combines internal programmes with pharmaceutical partnerships. Its announced collaborations include Pfizer on cardiovascular targets, GSK on respiratory and liver diseases, and Merck on inflammatory bowel disease, extending the applications of its somatic-genomics platform.
72
Team Members
2022
Founded
Biotechnology
Sector
Hybrid
Work Environment